- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alligator Bioscience AB (ATORX)
The Alligator Bioscience share price today is 0.0250, view ST ATORX stock exchange data. Track the latest Alligator Bioscience share price with real-time updates on ATORX stock performance including market cap, day range, 52-week range and dividend yield. Access ATORX charts, earnings dates and analyst estimates to support your investment decisions.
0.0250
-0.0007(-2.72%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0247
0.0272
52 wk Range
0.0192
5.5950
ATORX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.02470.0272
52 wk Range
0.01925.5950
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ATORX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Alligator Bioscience AB Earnings Call Summary for Q2/2026
- Alligator Bioscience abandons mitazalimab development, pivots to royalty model centered on HLX22, a HER2 antibody controlled by Shanghai Henlius.
- Cash stood at SEK 16.16M end-June; secured SEK 19M bridge loan in July and announced SEK 225M rights issue to fund operations through 2029 HLX22 launch.
- Company slashing staff and costs; expects HLX22 royalties of SEK 150M-450M annually starting 2030, with Phase III gastric cancer data due H2 2027.
- Stock rose 13% to $0.032 pre-market but remains down 99% year-over-year; management calls rights issue pricing versus HLX22 upside 'very interesting.'
- Rights issue subscription period Sept. 4-18; management says full subscription should fund operations until positive royalty territory, covering wind-down costs.
Last Updated: 26-08-2026, 07:26 pm
Read Full TranscriptEarnings
Latest Release
26-08-2026
EPS / Forecast
-0.06 / --
Revenue / Forecast
288K / --
Compare ATORX to Peers and Sector
Metrics to compare | ATORX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATORXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.2x | −2.7x | −0.4x | |
PEG Ratio | 0.00 | −0.06 | 0.00 | |
Price/Book | 4.7x | 2.9x | 2.6x | |
Price / LTM Sales | 23.1x | 23.9x | 3.0x | |
Upside (Analyst Target) | 124.0% | 132.5% | 48.7% | |
Fair Value Upside | Unlock | 1.3% | 7.0% | Unlock |
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 2 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, a monoclonal antibody that stimulates the 4-1BB receptor on T cells and NK cells in the tumor, which is in phase 1 for the treatment of solid metastatic cancers; and HLX22, an antibody that treats metastatic, gastric, and breast cancers, which is in phase 3 clinical trial. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; BioArctic AB; Henlius Biotech, Inc.; and Abclon Inc. The company was incorporated in 2000 and is headquartered in Lund, Sweden.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Alligator Bioscience (ATORX) Share Price Today?
The Alligator Bioscience share price today is 0.0250.
What is the current Alligator Bioscience (ATORX) share price and day range?
As of 05-09-2026, the Alligator Bioscience share price is 0.0250, with a previous close of 0.0257. The share price has ranged from 0.0247 to 0.0272 today, while the 52-week range spans from 0.0192 to 5.5950.
What Is the Alligator Bioscience Market Cap?
As of today, Alligator Bioscience market cap is 15.7000M.
What Is the Alligator Bioscience (ATORX) Share Price Target?
The average 12-month share price target for Alligator Bioscience is 0.0560, with a high estimate of 0.056 and a low estimate of 0.056. 0 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +124.00% Upside potential.
What Is Alligator Bioscience's Earnings Per Share (TTM)?
The Alligator Bioscience EPS (TTM) is -0.2450.
When Is the Next Alligator Bioscience Earnings Date?
Alligator Bioscience will release its next earnings report on 22-10-2026.
From a Technical Analysis Perspective, Is ATORX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Alligator Bioscience Trade On?
Alligator Bioscience is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for Alligator Bioscience?
The stock symbol for Alligator Bioscience is "ATORX."
How Many Times Has Alligator Bioscience Stock Split?
Alligator Bioscience has split 2 times.
How Many Employees Does Alligator Bioscience Have?
Alligator Bioscience has 11 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.